Robuta

A PARP inhibitor is a cancer drug that blocks the activity of poly(ADP-ribose) polymerase (PARP), a protein crucial for DNA repair.

Ovarian cancer continues to be the main cause of death among all gynecological tumors. After standard treatments, most of patients are destined to recur...

PARP inhibitors are a type of targeted cancer drug. Olaparib, niraparib and rucaparib are all examples of PARP inhibitors. Find out more about them.

A significant unresolved question is how vitamin A deprivation causes, and why retinoic acid fails to reverse, immunodeficiency. When depleted of vitamin A, T...

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in...

Individuals with mutations in the BRCA1 and BRCA2 (BRCA1/2) genes, particularly women, have a significantly higher risk for developing various types of cance...

PARPs have become important cancer drug targets. Cellomatics can support a wide range of PARP assays to suit your project.

Timeless interacts with PARP-1 to promote homologous recombination repair - Search Results - PubMed

AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.

A prospective 'PARP inhibitor' drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly...